Survival gain in cost-effectiveness studies

Comment

S Trippoli et al. J Clin Oncol. 2000.

. 2000 Sep 15;18(18):3318.

doi: 10.1200/JCO.2000.18.18.3318.

No abstract available

Comment in

Cost effectiveness of sunitinib.
Trippoli S, Messori A. Trippoli S, et al. J Clin Oncol. 2008 Dec 10;26(35):5829; author reply 5829-30. doi: 10.1200/JCO.2008.19.8101. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001342 No abstract available.

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
Hillner BE, Weeks JC, Desch CE, Smith TJ. Hillner BE, et al. J Clin Oncol. 2000 Jan;18(1):72-9. doi: 10.1200/JCO.2000.18.1.72. J Clin Oncol. 2000. PMID: 10623695
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE, Agarwala S, Middleton MR. Hillner BE, et al. J Clin Oncol. 2000 Apr;18(7):1474-80. doi: 10.1200/JCO.2000.18.7.1474. J Clin Oncol. 2000. PMID: 10735895 Clinical Trial.